2024-12-29
On December 18, 2024, the U.S. Food and Drug Administration (FDA) granted official approval for Ryoncil (remestemcel), developed by Mesoblast, making it the first mesenchymal stem cell (MSC) therapy to receive FDA approval. This marks a major milestone in the global stem cell therapy landscape.